Evolving gene delivery for T cell engineering and immunotherapy: From viral and non-viral vectors to AI-guided nanocarriers
Acta Pharmaceutica Sinica B · 2026-10
DOI: 10.1016/j.apsb.2026.10.029 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Pharmaceutica Sinica B, 2026-10. Verfasst von Pooyan Makvandi und 12 weiteren Autor:innen. Die Arbeit nennt 256 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Isfahan University of Medical Sciences, Korea Ministry of Science and ICT.
Abstract (Originalsprache)
T-cell engineering has emerged as a powerful immunotherapeutic strategy, particularly in oncology, and fundamentally relies on the design and optimization of gene delivery technologies. CAR-T cell therapy, TCR engineering, and other innovative approaches are considered as part of this concept. This review provides an integrated framework linking gene delivery strategies to the core principles of T cell engineering. Both viral and non-viral vectors play complementary roles in T cell engineering. Viral platforms provide high transduction efficiency and stable gene expression, whereas non-viral platforms offer improved safety, scalability, and tunable design flexibility. Owing to their tunable physicochemical properties, biocompatibility, and versatile surface functionality, nano-based vectors such as lipid-, polymer-, and nanoparticle-based systems can enable efficient gene encapsulation and controlled release, thereby enhancing transfection efficiency and therapeutic outcomes. This review comprehensively explores the paradigm shift toward in vivo gene delivery and highlights the emerging role of artificial intelligence in guiding target discovery, receptor design, and safety optimization. Together, these insights outline a forward-looking roadmap for developing intelligent, efficient, and clinically translatable T cell therapies.
Förderung
- Isfahan University of Medical Sciences
- Korea Ministry of Science and ICT
Zitieren
APA
Makvandi, P., Zamani, S., Fadaie, M., Najafi, M. B., Mofidfar, M., Dana, N., Avazzadeh, A., Mahmoudi, E., Deng, W., Huang, R., Ling, D., Kang, H., & Rahimmanesh, I. (2026). Evolving gene delivery for T cell engineering and immunotherapy: From viral and non-viral vectors to AI-guided nanocarriers. Acta Pharmaceutica Sinica B. https://doi.org/10.1016/j.apsb.2026.10.029
Vancouver
Makvandi P, Zamani S, Fadaie M, Najafi MB, Mofidfar M, Dana N, et al. Evolving gene delivery for T cell engineering and immunotherapy: From viral and non-viral vectors to AI-guided nanocarriers. Acta Pharmaceutica Sinica B. 2026. doi:10.1016/j.apsb.2026.10.029
BibTeX
@article{Makvandi2026,
author = {Makvandi, Pooyan and Zamani, Saeed and Fadaie, Mahmood and Najafi, Majed Bahri and Mofidfar, Mohammad and Dana, Nasim and Avazzadeh, Amirmohammad and Mahmoudi, Elham and Deng, Wuquan and Huang, Rongqin and Ling, Daishun and Kang, Heemin and Rahimmanesh, Ilnaz},
title = {Evolving gene delivery for T cell engineering and immunotherapy: From viral and non-viral vectors to AI-guided nanocarriers},
journal = {Acta Pharmaceutica Sinica B},
year = {2026},
doi = {10.1016/j.apsb.2026.10.029}
}
EUVIMED